Marta Salichs

Marta Salichs

Auto-generated profile, based on publicly available information

Marta Salichs

R&D Department Ecuphar Veterinaria SLU (Animalcare Group) Sant Cugat del Vallès Barcelona Spain

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2013 in Journal of Animal Science
Verified
Journal Article
Closed access
PDF file
MSM. Salichs
M. Salichs
DSD. Sabaté
D. Sabaté
JHJosep Homedes
Josep Homedes
The purpose of this study was to evaluate the efficacy of an oral solution of ketoprofen administered in drinking water at a lower dose as a complement to antimicrobial therapy in a mild outbreak of porcine respiratory disease complex. The study was performed with 120 pigs with rectal temperature between 39.9 and 41°C and at least 1 sign indicating porcine respiratory disease complex (dyspnea, cough, nasal discharge, or depression). Animals were randomly allocated in 2 groups (treated and control group). Animals in both groups received etiological therapy with doxycycline at 10 mg·kg–1 in drinking water for 5 d. The animals in the treated group also received 1.5 mg·kg–1 of ketoprofen during the first 3 d. The reduction in rectal temperature in the treated group was significantly greater during the days of ketoprofen administration and up to 1 d after the end of treatment (P < 0.05). The percentage of dyspneic animals was significantly less (P < 0.05) in the treated group from d 2 to 5 of the study. Also, a significant improvement regarding depression and cough was seen in the animals of the treated group. No statistically significant (P > 0.05) differences were evidenced in productive variables. In conclusion, oral treatment with ketoprofen at 1.5 mg·kg–1 in combination with antimicrobial therapy was found to be a clinically effective approach in outbreaks of mild porcine respiratory disease complex. Copyright © 2013. American Society of Animal Science .

4 October 2023 in Parasites & Vectors
Verified
Journal Article
Open access
PDF file
MBMarta Baxarias
Marta Baxarias
GDGiulia Donato
Giulia Donato
CMCristina Mateu
Cristina Mateu
MSMarta Salichs
Marta Salichs
JHJosep Homedes
Josep Homedes
LSLaia Solano-Gallego
Laia Solano-Gallego
Background: Domperidone (Leisguard®) is an immunomodulatory drug used as a preventive measure in healthy dogs. However, no studies have been published in healthyLeishmania infantum-seropositive dogs. The aim of this study was to evaluate the clinical efficacy and safety of domperidone as immunotherapy inLeishmania-seropositive healthy dogs.Methods: Sixty-seven dogs were treated with domperidone at 0.5 mg/kg and 44 dogs received placebo, once daily for 4 consecutive weeks. Monthly treatments were repeated every 4 months until the end of the 1-year follow-up period. Veterinary examinations were performed on days 0, 30, 120, 150, 240, 270 and 360. Samples of blood and urine were collected on days 0, 120, 240 and 360 for routine laboratory tests and quantitative in-house ELISA for the detection ofL. infantum-specific antibodies. Furthermore,Leishmaniareal-time PCR and IFN-γ ELISA were performed at day 0 and the end of the study. Dogs that developed disease were withdrawn from the study and classified as sick dogs. Adverse drug reactions were reported.Results: Thirty dogs developed disease during the follow-up period: 13/67 (19.4%) in the group treated with domperidone and 17/44 (38.6%) in the placebo-treated group (P = 0.03). Low-seropositive dogs treated with domperidone (4/40, 9.1%) were significantly less likely to develop disease compared to low-seropositive dogs treated with placebo (7/24, 29.2%;P = 0.04), while no differences were found between domperidone (9/23, 39.1%) and placebo (10/20, 50%) in medium- to high-seropositive dogs. At the end of the study, a higher proportion ofLeishmaniaPCR-positive dogs was observed in the placebo-treated group (16/33, 48.5%) compared to the domperidone group (13/51, 25.5%;P = 0.04). Furthermore, low-seropositive dogs treated with domperidone with an increase of IFN-γ concentration presented a higher increase than those treated with placebo at the end of the study. Four dogs treated with domperidone presented self-limiting diarrhea.Conclusions: Healthy dogs with lowL. infantumantibody levels treated with domperidone were less likely to develop disease compared to placebo-treated dogs. Furthermore, domperidone presented a good safety profile.Graphical

15 July 2025 in Research in Veterinary Science
Verified
Journal Article
Open access
MSMarta Salichs
Marta Salichs
AAAntonio Arcas
Antonio Arcas
JHJosep Homedes
Josep Homedes
CCCristina Costa-Farré
Cristina Costa-Farré
Postoperative pain is most effectively managed pre-emptively and enflicoxib characteristics make it a good candidate to control it with a single administration. To assess the efficacy of enflicoxib in the control of postoperative pain and inflammation associated with orthopaedic surgery, twenty-eight dogs were randomised to receive 8 mg/kg enflicoxib (n = 14) orally the day before surgery, or 0.2 mg/kg meloxicam (n = 14) subcutaneously at induction and orally at 0.1 mg/kg daily every 24 h for seven days. Veterinarians assessed efficacy with the Glasgow Composite Pain Scale Short-Form (GCPS-SF) at 1.5, 3, 5, 8, 24 and 168 h after surgery. Visual analog scales (VAS) were also used to assess pain at rest, pain at palpation and inflammation. Enflicoxib showed to be non-inferior to meloxicam in the GCPS-SF total scores, at each time point, and the area under the curve (GCPS-SF AUC) for the first 24 h. No differences were observed in VAS scores at any time point after surgery or the global efficacy as assessed by the veterinarians, or the dog's wellbeing assessed by the owners. Enflicoxib administered 24 h before surgery is efficacious and safe for the control of postoperative pain associated with orthopaedic surgery. One single dose would control postoperative pain and inflammation for one whole week. The results need further confirmation in larger sample size studies.

8 October 2024 in Veterinary Dermatology
Verified
Journal Article
Open access
MSMarta Salichs
Marta Salichs
SBShea Beasley
Shea Beasley
JHJosep Homedes
Josep Homedes
Background: Anal sac impaction is common in dogs. Manual expression may be effective, yet recurrence can be problematic. To facilitate physiological emptying of the sacs, it is important to maintain bulky stool consistency. Objectives: The study evaluated if supplementation with a complementary feed product formulated as a chew containing Bacillus velezensis C‐3102 and fibre sources, reduced anal sac impaction recurrence. Animals: Thirty‐five client‐owned dogs with anal sac impaction were enrolled. Materials and Methods: Prospective, randomised, negative controlled field clinical trial with 22 dogs receiving the chew orally for 90 consecutive days and 13 dogs with no treatment. Dogs were evaluated on Day (D) 30, 60, 90 and 120 for the presence of clinical signs of anal sac impaction and the need to empty the sacs. Any animal that required manual expression of the sacs was classified as a failure and was withdrawn from the study. Results: The cumulative percentage of failures in the untreated group increased steadily from the first follow‐up visit on D30 (15%) to the last visit on D120 (61.5%). However, in the group receiving the chew the cumulative percentage of failures increased at a much slower rate and stabilised at 19% from the D90 visit (last administration day) until the end of the study on D120, with statistically significant differences ( p = 0.025). Animals receiving the chew also showed reduction in clinical signs. Conclusion and Clinical Relevance: The probiotic and fibre chew was a safe and effective management option for recurrent anal sac impaction in dogs.

1 March 2026 in Journal of the American Veterinary Medical Association
Verified
Journal Article
Open access
MSMarta Salichs
Marta Salichs
ABAnabel Blasco
Anabel Blasco
LBLlorenç Badiella
Llorenç Badiella
CCCristina Costa-Farré
Cristina Costa-Farré
PSPedro Sousa
Pedro Sousa
JHJosep Homedes
Josep Homedes
Objective: To demonstrate that a single dose of enflicoxib is noninferior to daily carprofen for the control of pain and inflammation in dogs undergoing soft tissue surgery. Methods: A prospective, multisite, blinded, randomized, controlled, parallel-group, noninferiority field study was performed to assess the efficacy and safety of enflicoxib in the control of pain and inflammation associated with soft tissue surgery. Two hundred fifteen dogs were randomized to receive 8 mg/kg of enflicoxib PO the day before surgery or 4 mg/kg of carprofen SC at induction and PO daily for 5 days. Veterinarians assessed efficacy with the short form of the Glasgow Composite Pain Scale (SF-GCPS) at 2, 5, 8, and 24 hours and 2, 3, and 5 days after surgery. The visual analog scale was used to assess inflammation. Demeanor, analgesia, and mobility were assessed daily by the owners. Results: Enflicoxib was noninferior to carprofen in the SF-GCPS area under the curve for the first 48 hours. Inflammation and SF-GCPS total scores were within the clinically relevant margin at each time point. No differences were observed in inflammation or in the owner assessment. Conclusions: Enflicoxib administered 24 hours before surgery is safe and efficacious for the control of postoperative pain associated with soft tissue surgery. Clinical Relevance: A single preoperative dose of enflicoxib is an alternative for postoperative management in dogs undergoing soft tissue surgery, offering a simplified treatment regimen without compromising outcomes.

8 May 2026 in Veterinary Dermatology
Verified
Journal Article
Open access
MSMarta Salichs
Marta Salichs
SBShea Beasley
Shea Beasley
HGHanne Gagroo
Hanne Gagroo
ASAlix Simons
Alix Simons
THTim Henkens
Tim Henkens
ICIngmar Claes
Ingmar Claes
Background: Lactobacillaceae have shown promise with their potential to outcompete pathogens and restore a healthy microbial balance in otitis externa (OE). Hypothesis/Objectives: This study aimed to evaluate the presence of viable Lactobacillaceae over time and in vitro ability to inhibit growth of common OE pathogens. Animals: Fifteen healthy dogs were enrolled and randomised into five groups ( n = 3 per group) to receive six probiotic ear drops containing live Lactiplantibacillus plantarum YUN‐V2.0 and Lacticaseibacillus rhamnosus YUN‐S1.0. Materials and Methods: Ear swabs were taken 24, 48, 72, 96 h and 7 days post single application for culturing. For pathogen inhibition, clinical isolates of Pseudomonas aeruginosa , Staphylococcus pseudintermedius and Malassezia pachydermatis were tested against the probiotic ear drop and antimicrobial disks of florfenicol 30 μg, gentamicin 30 μg, marbofloxacin 5 μg, miconazole 10 μg, neomycin 120 μg and terbinafine 1.5 μg. Results: A relatively basal low abundance of commensal and Lactobacillaceae micro‐organisms was detected (1.34 × 10 3 colony‐forming units [cfu]/mL). At 24 h post‐application, Lactobacillaceae increased significantly (2.3 × 10 6 cfu/mL; p < 0.001), and remained above 10 5 cfu/mL at 1 week post‐application (1.6 × 10 5 cfu/mL). Lactobacilli demonstrated better growth inhibition of P. aeruginosa than gentamicin and marbofloxacin, and of S. pseudintermedius than gentamicin, neomycin and marbofloxacin. For M. pachydermatis similar growth inhibition versus miconazole and terbinafine was observed. Conclusions and Clinical Relevance: These results suggest that probiotic strains exhibit excellent retention and can inhibit the growth of S. pseudintermedius , P. aeruginosa , and M. pachydermatis .